In a late-stage trial, Insmed’s small molecule DPP1 inhibitor cut yearly exacerbation rates by around 20% in bronchiectasis ...

Driven by growing market demand and an improving supply chain, the global weight-loss drug market is expected to hit $150 ...

Amgen on Tuesday secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two ...

J&J announced Wednesday its late-stage experimental drug seltorexant met all primary and secondary endpoints in a Phase III ...

AstraZeneca announced Wednesday Phase I trial data for its PCSK9 inhibitor, AZD0708, which showed a statistically significant ...

As we near the end of second quarter of 2024, the initial public offerings among biotechs have slowed, but the market is ...

Merck announced on Wednesday it is acquiring privately held biotech EyeBio in a potential $3 billion bid to diversify its ...

The insights AI affords can potentially boost sustainability, but it’s unclear whether these gains outweigh the technology’s ...

Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients ...

With back-to-back victories in IgA nephropathy and C3 glomerulopathy, Novartis on Saturday said it is planning to make ...

Johnson & Johnson’s deal for Numab Therapeutics’ bispecific antibody NM26, slated to enter Phase II studies, comes on the ...

Flagging a risk of hypoglycemia, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Friday did not recommend ...